{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-007428","form_type":"8-K","ticker":"PBSV","cik":"0001304161","company_name":"Pharma-Bio Serv, Inc.","filed_at":"2023-05-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.323492+00:00","generated_at":"2026-06-14T10:15:54.503387+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Pharma-Bio Serv elects Irving Wiesen as Class I director at 2023 annual meeting","bullets":["Irving Wiesen elected Class I director with 7,477,036 for and 11,696,947 withheld; 515,852 broker non-votes.","Ratification of Crowe PR PSC as auditor for FY ending Oct 31, 2023 passed with 14,344,226 for, 1,492,688 against, 3,852,921 abstain.","Withheld votes exceeded for votes in director election; elected by plurality rule."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-007428","json":"https://secwatch.observer/filing/0001654954-23-007428.json","markdown":"https://secwatch.observer/filing/0001654954-23-007428.md","text":"https://secwatch.observer/filing/0001654954-23-007428.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1304161/000165495423007428/0001654954-23-007428-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1304161/000165495423007428/pbsv_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T10:15:54.503387+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"17c55cf7159c0d9f33b027a6c4298d65e8e6d6ee","claim":"Pharma-Bio Serv, Inc. shareholders approved Ratification of Crowe PR PSC as independent auditors at the 2023-05-31 meeting.","evidence_excerpt":"The ratification of the selection of Crowe PR PSC as the Company's independent certified public accountants for the fiscal year ending October 31, 2023 received the following votes: Votes For Votes Against Abstain 14,344,226 1,492,688 3,852,921 There were no broker non-votes on this proposal.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1304161/000165495423007428/0001654954-23-007428-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-31"}],"fact_type":"shareholder_vote"},{"claim_id":"9aa99a4de9663bb8374882293a7972619cd48fc9","claim":"Pharma-Bio Serv, Inc. shareholders approved Election of Irving Wiesen as a Class I director at the 2023-05-31 meeting.","evidence_excerpt":"Irving Wiesen was elected as a Class I director by a plurality of the shares present in person or represented by proxy at the Annual Meeting and entitled to vote. Mr. Wiesen shall serve as a Class I director until the 2026 Annual Meeting of Stockholders or until his successor is duly elected and qualified. The votes for this proposal were as follows: Nominee Votes For Votes Withheld Irving Wiesen 7,477,036 11,696,947 There were 515,852 broker non-votes on this proposal.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1304161/000165495423007428/0001654954-23-007428-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-31"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}